This week, our CEO represented us at BIO-Europe Spring in Barcelona, a key moment as we launch our Series A funding round. Connecting with the biotech community’s key players, we received motivating feedback, which affirms the strong industry resonance of our mission – advance RNA-based therapies to stop the progression of debilitating retinal diseases and fight blindness.
Stay tuned for upcoming updates – together, we’re heading towards a brighter future!
Related Posts
